Results 231 to 240 of about 444,347 (295)

Dihydropyrimidine angiotensin II receptor antagonists

Journal of Medicinal Chemistry, 1992
The discovery of the nonpeptide angiotensin II (AII) receptor antagonist losartan, previously called DuP 753, has stimulated considerable interest in the synthesis of novel analogs of this compound. Our efforts in this area have resulted in the discovery of dihydropyrimidines as potent AII receptor antagonists. The chemistry leading to this novel class
K S, Atwal, S Z, Ahmed, J E, Bird, C L, Delaney, K E, Dickinson, F N, Ferrara, A, Hedberg, A V, Miller, S, Moreland, B C, O'Reilly   +9 more
openaire   +2 more sources

Nonpeptide Angiotensin II Receptor Antagonists

American Journal of Hypertension, 1990
Although the most direct way to interfere with the renin-angiotensin system (RAS) is at the level of the angiotensin II (AII) receptor, the currently available AII receptor antagonists are peptides still retaining significant agonistic properties with the obvious drawbacks of limited stability and lack of oral activity.
P B, Timmermans, D J, Carini, A T, Chiu, J V, Duncia, W A, Price, G J, Wells, P C, Wong, R R, Wexler, A L, Johnson   +8 more
openaire   +2 more sources

Selective blockade of angiotensin responses in the rabbit isolated vas deferens by angiotensin receptor antagonists.

Journal of Pharmacology and Experimental Therapeutics, 1990
We examined the effect of two angiotensin receptor antagonists on neuromodulatory and prostaglandin-producing effects of angiotensin II in the rabbit isolated vas deferens because prior studies have established that angiotensins selectively influence the
G. Trachte, C. Ferrario, M. Khosla
semanticscholar   +1 more source

Angiotensin II receptor antagonists and receptor subtypes

Trends in Endocrinology & Metabolism, 1992
Recently discovered nonpeptide angiotensin II receptor antagonists represent a new class of potential drugs for the treatment of hypertension and congestive heart failure. Further, these antagonists have been successfully used as selective research tools for physiologic studies of angiotensin H and defining angiotensin II receptor subtypes.
P C, Wong, A T, Chiu, J V, Duncia, W F, Herblin, R D, Smith, P B, Timmermans   +5 more
openaire   +2 more sources

Angiotensin II Receptor Antagonists

High Blood Pressure & Cardiovascular Prevention, 2007
Stroke is a devastating disease that heavily affects overall cardiovascular mortality and quality of life in surviving patients, and has a relevant burden on healthcare systems. Recent data derived both from large epidemiological surveys and from the analysis of events occurring in the clinical trials on hypertension, performed over the last 10 years ...
Giuliano Tocci, Francesca Giovannelli, Caterina Facciolo   +2 more
openaire   +1 more source

The Other Angiotensin II Receptor: AT2R as a Therapeutic Target.

Journal of Medicinal Chemistry, 2020
The active hormone of the renin-angiotensin system (RAS), angiotensin II (Ang II) is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and ...
L. Juillerat-Jeanneret
semanticscholar   +1 more source

Angiotensin receptor antagonists

Abstract The renin–angiotensin–aldosterone system (RAAS) is activated in patients with heart failure and contributes to many of the detrimental effects seen in these patients. Antagonists to the angiotensin II type-1 (AT1)-receptor (ARBs) provide a pharmacologically different mechanism of inhibiting the RAAS to ACE inhibitors.
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source

Angiotensin receptor antagonists.

Australian family physician, 2000
Angiotensin receptor antagonists are a relatively new class of cardiovascular drugs for which the clinical application has not yet been completely defined.This article reviews the pharmacology of the various angiotensin receptor antagonists available in Australia, including their mode of action, side effects and potential drug interactions.Angiotensin ...
W, Wong, L, Howes
openaire   +1 more source

Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects

Nature Reviews Nephrology, 2021
J. Barrera-Chimal, I. Lima-Posada, G. Bakris, F. Jaisser   +3 more
semanticscholar   +1 more source

Angiotensin II receptor antagonists - antihypertensive agents

Expert Opinion on Investigational Drugs, 1997
Blockade of the renin-angiotensin system (RAS) is now recognised as an effective approach for the treatment of hypertension and congestive heart failure (CHF). Today, it is possible to antagonise the effects of angiotensin II more specifically by blocking its receptors using non-peptide receptor antagonists. These compounds, which at first were used to
M, Burnier, H R, Brunner
openaire   +2 more sources